T he identification of heart failure (HF) with preserved ejection fraction (HFpEF) can be difficult as there is no primary diagnostic criterion equivalent to that of a reduced ejection fraction (EF) in the other principal HF phenotype, that is, HF with reduced ejection fraction (HFrEF). 1, 2 This has presented a particular challenge in clinical trials, with the concern that a diagnosis of HFpEF based on the presence of typical HF symptoms and physical exam signs alone may have led to the inclusion of heterogeneous patients, some of which may not have had HF. 3 This heterogeneity has also been suggested as one of the reasons for the neutral results of several clinical trials of varied pharmacological interventions to reduce morbidity and mortality in HFpEF. [4] [5] [6] As a result, new HF guidelines and recent clinical trials have required more than typical symptoms and signs to make a diagnosis of HFpEF, adding the need to demonstrate elevation of circulating natriuretic peptide concentrations and the presence of typical cardiac structural abnormalities, for example, left atrial enlargement. [7] [8] [9] However, patients with atrial fibrillation (AF) represent a challenge in HF trials, as they may have symptoms typical of HF, have raised levels of natriuretic peptides and usually have an atrial enlargement. 10, 11 Inclusion of patients with AF who do not truly have HFpEF might result in a subgroup of participants at low risk of HF-related events and who are unresponsive to therapy targeted at HF. To deal with this concern, more recent HFpEF trials have used a higher natriuretic peptide threshold for inclusion of patients with AF and in some instances have capped the proportion of patients with AF. 7 Using this approach, it is hoped that HFpEF patients with AF will experience similar rates of HFrelated events as HFpEF patients without AF.
We have tested the validity of this hypothesis using pooled data from the I-Preserve (Irbesartan in Heart Failure With Preserved Systolic Function) and TOPCAT (Treatment of Preserved Cardiac Function in Heart Failure With an Aldosterone Antagonist) trials to investigate whether the prognostic value of NT-proBNP differs for HFpEF patients with and without AF. It should be noted that neither of these trials applied specific NTproBNP inclusion criteria for patients with AF.
METHODS
I-Preserve and TOPCAT were randomized trials that examined the effects of the angiotensin II receptor antagonist, irbesartan, and the aldosterone antagonist spironolactone, respectively, on morbidity and mortality in patients with HFpEF. 6, 12 The rationale, design, and principal results of the 2 trials have been reported. 5, 6, [12] [13] [14] Both studies were approved by the ethics committee at each study center before patient enrollment, and all participating patients provided written informed consent.
Study Patients
Patients enrolled in the trials were ≥60 years of age (≥50 years of age in TOPCAT) and had a left ventricular EF ≥45%. For I-Preserve, in addition to HF symptoms, patients who had been hospitalized for HF during the previous 6 months were required to have current New York Heart Association class II, III, or IV symptoms and echocardiographic, electrocardiographic or chest X-ray findings supporting a diagnosis of HF and underlying structural heart disease; as well, if not recently hospitalized for HF, patients were required to have ongoing New York Heart Association class III or IV symptoms. 12 In I-Preserve, NT-proBNP was measured at baseline using Elecsys 2010 (Roche Diagnostic; Basel, Switzerland) in a central laboratory (LabCorp Belgium) in most (84%) patients but there was no formal natriuretic peptide entry criterion, and NT-proBNP results were not reported to investigators during randomization. To be eligible for TOPCAT, patients were required to have at least one sign and at least one symptom of HF, and a history of either HF hospitalization within prior 12 months (defined by the investigator) or elevated natriuretic peptide levels (B-type natriuretic peptide [BNP] ≥100 pg/mL or NT-proBNP ≥360 pg/mL). The BNP and NT-proBNP inclusion threshold were the same for patients with and without AF. For both trials, exclusion criteria included a systolic blood pressure <100 or >160 mm Hg or a diastolic blood pressure >95 mm Hg despite antihypertensive therapy; a creatinine level >2.5 mg/dL (221 μmol/L) or a potassium concentration >5.2 mmol/L (>5.0 mmol/L in TOPCAT). In the current study, we only included patients with a measurement of NT-proBNP at baseline. We also excluded TOPCAT patients enrolled outside of the Americas because of uncertainty about the diagnosis of HF, evidence of treatment nonadherence and atypically low event rates in Russia and Georgia. 15 
WHAT IS NEW?
• In patients with heart failure with preserved ejection fraction, the association between level of NTproBNP (N-terminal pro-B-type natriuretic peptide) and outcomes varies significantly according to the presence of atrial fibrillation (AF), with higher levels of NT-proBNP less predictive among individuals with AF, compared with those without AF. • Absolute event rates are low in patients with heart failure with preserved ejection fraction with an NTproBNP level <400 pg/mL.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Clinicians should be aware that in patients with heart failure with preserved ejection fraction, higher NT-proBNP levels are of less prognostic importance in patients with AF than in those without.
• In clinical trials, a higher entry natriuretic peptide level should be required for heart failure with preserved ejection fraction patients with AF, compared with those without AF, to ensure similar event rates in the 2 groups.
Study Procedures
We examined the relationship between outcomes and baseline NT-proBNP category (NT-proBNP bands) and using NT-proBNP as a continuous measure (modeled as a restricted cubic spline model-see below). Patients were subgrouped into the following NT-proBNP bands at baseline, based on a prior similar analysis in patients with HFrEF: <400, 400 to 999 (reference group), 1000 to 1999, and ≥2000 pg/mL and applied these separately in patients with and without AF. 16 In Tables 1 and 2 , the <400 pg/mL band is further divided into <200 and 200 to 399 pg/mL, given the large proportion of HFpEF patients without AF with NT-proBNP <400 pg/mL. AF was defined by its presence on the baseline ECG. Moreover, in Appendix Table I in the Data Supplement, we additionally stratified baseline characteristics by each NT-proBNP band and AF status.
Outcomes
The primary outcome for this study was time to the first occurrence of the composite of cardiovascular death or HF hospitalization. Each component of this composite was also analyzed separately. Finally, we examined death from any cause which was a prespecified secondary end point in both trials.
Statistical Analysis
Baseline characteristics are presented as means with SDs for continuous variables and frequencies and percentages for categorical variables. Unadjusted as well as ageadjusted event rates are reported per 100 patient-years (py) of follow-up according to AF status at baseline and NT-proBNP band. Cox proportional hazard models were used to calculate hazard ratios (HRs) and cumulative event curves according to level of NT-proBNP, in patients with and without AF, with 400 to 999 pg/mL as a reference group. The covariables in adjusted Cox regression models included age, sex, race (white versus all other), geographic region, study drug, New York Heart Association class, EF, heart rate, systolic blood pressure, body mass index, estimated glomerular filtration rate, HF duration, ischemic cause, history of recent HF hospitalization, and history of myocardial infarction. These variables were chosen because of their prognostic significance identified in a prior analysis of the I-Preserve dataset and their availability in both datasets.
14 Log (−log(survival)) curves were used to evaluate the proportional hazard assumption. The assumption of linearity of continuous variables (age, estimated glomerular filtration rate, and left ventricular EF) was tested by including variables of age, estimated glomerular filtration rate, and left ventricular EF squared. These were found to be valid unless otherwise specified. The relationship between NT-proBNP as a continuous variable and the outcomes of interest, according to the presence of AF, adjusted for other prognostic variables, is shown with NT-proBNP modeled as a restricted cubic spline (with NT-proBNP =600 pg/ mL as the reference value). All P values are 2-sided, and a P value of <0.05 was considered significant. Analyses were performed using Stata version 14 (Stata Corp, College Station, TX).
RESULTS

Baseline Characteristics
The study cohort comprised 3835 patients with HFpEF (3479 from I-Preserve and 356 from TOPCAT-Americas), of which 719 (19%) had AF on their baseline ECG (597 from I-Preserve and 122 from TOPCATAmericas). Median (Q1-Q3) NT-proBNP concentration was 1286 pg/mL (778-2072) in those with AF and 288 pg/mL (122-704) in those without (P<0.0001). Patients with AF were older (74 versus 71 years), more often male (47% versus 39%), had a better overall New York Heart Association class profile, more likely to have a history of HF hospitalization (57% versus 40%) but less likely to have a history of myocardial infarction (17% versus 26%); all P<0.001 (Table 1) . When assessing each NT-proBNP band separately (Appendix Table I in the Data Supplement), those in the higher bands had lower systolic blood pressure, body mass index, and worse kidney function. Most importantly, they were more likely to have a prior HF hospitalization, myocardial infarction, and to be treated with β-blockers and diuretics. The pattern of differences, according to AF status, was largely consistent across NT-proBNP bands (with the possible exception of patients with AF in the lowest band, here the number of participants was small).
The proportion of patients in each predefined NTproBNP band differed markedly according to AF status: only 9% of patients with AF had an NT-proBNP concentration <400 pg/mL, compared with 60% of patients without AF (indeed, 39% patients without AF had NTproBNP <200 pg/mL). Conversely, the proportion of AF patients with an NT-proBNP level in the 2 higher bands was greater than among patients without AF: 36% versus 10%, respectively, in the 1000 to 1999 pg/mL band and 27% versus 8%, respectively, in the ≥2000 pg/mL band (Table 1) .
Crude (Unadjusted) Event Rates According to NT-proBNP Concentration
Overall, the annualized rate of each of the outcomes of interest was substantially higher in patients with AF compared to those without (Table 2) .
Primary Composite Outcome
In the lowest NT-proBNP bands (<400 pg/mL), the crude rate of the primary composite outcome of cardiovascular death or HF hospitalization was higher in patients with AF compared to those without AF (8.0 versus 3.2 per 100 py). In the next NT-proBNP band (400-999 pg/ mL), the crude event rate was similar in patients with and without AF (8.9 versus 8.0 per 100 py) but in the 2 higher NT-proBNP bands the crude event rates were lower in patients with AF, compared with those without 11.4 versus 13.2 per 100 py in band 1000 to 1999 pg/ mL and 17.4 versus 25.6 per 100 py in band ≥2000 pg/ mL (Figure 1 ).
Cardiovascular Mortality
In the lowest NT-proBNP bands (<400 pg/mL), the crude rate of cardiovascular death was also higher in patients with AF compared with those without AF (4.9 versus 1.7 per 100 py) but was slightly lower among patients with AF compared with those without AF in the next 2 NT-proBNP bands (400-999 pg/mL; 3.1 versus 4.2 per 100 py; 1000-1999 pg/mL; 5.4 versus 6.6 per 100 py) and considerably lower among patients with AF in the highest band (≥2000 pg/mL): 9.4 versus 13.7 per 100 py ( Figure 1 ).
All-Cause Mortality
The event rates across NT-proBNP bands seen for cardiovascular mortality were very similar to that observed for all-cause mortality (Figure 1 ).
HF Hospitalization
The crude rate of HF hospitalization was higher in patients with AF compared with those without AF (5.8 versus 1.9 per 100 py) in the lowest NT-proBNP bands (<400 pg/mL). In the 400 to 999 pg/mL NT-proBNP band, the rate was higher in the AF group (6.9 versus 4.7 per 100 py) whereas in the 1000 to 1999 pg/mL the rate was identical (8.2 versus 8.2 per 100 py). The rate of HF hospitalization was considerably lower among patients with AF in the highest band (≥2000 pg/mL): 10.5 versus 16.2 per 100 py (Figure 1) .
In summary, the rate of each of the outcomes of interest was broadly similar in the 2 middle NT-proBNP bands (400-999 and 1000-1999 pg/mL) but different in the lowest and highest bands (Figure 1 ). In the highest band, each outcome was substantially higher in patients without AF compared with those with AF. The reverse was seen in the lowest NT-proBNP band (using <400 pg/mL as the lowest band). However, the numbers of individuals with AF in that band were small, and the estimates of event rates are subject to uncertainty.
Unadjusted and Adjusted HRs According to NT-proBNP Concentration
Unadjusted and adjusted HR for each NT-proBNP band (using NT-proBNP 400-999 pg/mL as the reference) within each rhythm stratum are shown in Table 2 (and adjusted HR in Figure 2 ). Two distinct patterns were observed: one for cardiovascular and all-cause mortality and another for the primary composite outcome and HF hospitalization.
Examination of the adjusted HR showed that the relative risk of cardiovascular death was elevated to a similar extent in patients with and without AF in each of the upper 2 NT-proBNP bands (1000-1999 and ≥2000 pg/mL) compared with the reference band (400-999 pg/mL): HRs for patients without AF 1.40 (1.04-1.90) and 2.74 (2.06-3.65), respectively, and for patients with AF 1.55 (0.94-2.54) and 2.48 (1.51-4.06), respec- ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimate glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter defibrillator; MRA, mineralocorticoid receptor antagonist; NTproBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart Association functional class. tively. A similar pattern was seen for all-cause mortality. However, a different pattern was seen for the other 2 outcomes, with this difference explained by HF hospitalization. There was a greater elevation of risk among patients without AF, compared with those with AF, in the higher NT-proBNP bands (compared with the reference band). For example, for the primary composite outcome, the HRs in the 2 higher NT-proBNP bands in patients without AF were 1.45 (1.15-1.82) and 2.55 (2.03-3.20), respectively, compared with 1.08 (0.77-1.51) and 1.51 (1.07-2.13), respectively. When looking at risk of HF hospitalization separately, we found no significant relation with levels of NT-proBNP in patients with AF, as is depicted in the restricted cubic spline analysis looking at NT-proBNP as a continuous variable. Patients with AF in the lowest NT-proBNP band (<400 pg/mL) generally had a higher relative risk of each outcome compared with patients without AF in this band. However, the numbers of patients with AF in this band were small and subject to uncertainty.
Adjusted Restricted Cubic Spline Analyses of Outcomes Related to NT-proBNP Concentration
Restricted cubic spline analysis, adjusted for other prognostic variables and using 600 pg/mL as the NT-proBNP reference value, confirmed that the pattern of risk related to NT-proBNP was different for cardiovascular and all-cause mortality compared with the pattern for the primary composite outcome and HF hospitalization (Figure 3) . Specifically, there was no relationship For unadjusted and adjusted hazard ratios, reference NT-proBNP band is 400-999 pg/mL (light-gray band). Adjusted for age, sex, race (white vs all other), LVEF, NYHA III/IV vs II, HR, SBP, BMI, eGFR, history of HF hospitalization, history of MI, history of stroke, history of diabetes mellitus, and history of COPD, randomized treatment. AF indicates atrial fibrillation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; and SBP, systolic blood pressure.
*Event rates and HR not calculated for patients with AF in view of the small numbers; event rates/HRs given in text and in figures for combined groups, ie, NTproBNP <400 pg/mL. between NT-proBNP level and rate of HF hospitalization in the participants with AF (and little, if any, relationship between NT-proBNP level and the composite outcome, compared with cardiovascular death alone).
DISCUSSION
In this study, we used pooled data from I-Preserve and TOPCAT-Americas and found that, overall, patients with HFpEF and AF on their baseline ECG had much higher crude rates of all outcomes than patients without AF. This is strikingly different than observed recently in patients with HFrEF, where the overall event rates in patients with and without AF were similar. 16 However, this difference in HFpEF was largely explained by the high proportion of patients without AF who had a relatively low NT-proBNP at baseline. Almost 60% of the non-AF patients with HFpEF had an NT-proBNP concentration <400 pg/mL, compared with 9% of patients with AF. These findings are also quite different than found in our analysis of patients with HFrEF, where these proportions were 8% and 3%, respectively. 16 In addition, when just patients with NT-proBNP levels ≥400 pg/mL were examined, we found that the risk associated with NT-proBNP differed between HFpEF patients with and without AF. The picture was somewhat different in unadjusted and adjusted analyses because HFpEF patients with and without AF are quite dissimilar in their clinical characteristics. The relative risk related to AF also varied according to which end point was examined with, in the adjusted analyses, a linear increase in risk of death (cardiovascular and allcause) up to an NT-proBNP of 2000 pg/mL, with some plateauing thereafter. This contrasted to the lack of a significant association between NT-proBNP levels and HF hospitalization in patients with AF. This contributed to a less steep relationship between NT-proBNP and the composite of cardiovascular death or HF hospitalization. This dissociation between these different outcomes is also different than observed in HFrEF, where the risks related to increasing NT-proBNP levels increased similarly in patients with and without AF and for each of the different end points described. 16 We think these findings are scientifically interesting and clinically relevant, especially for the design of clinical trials in HFpEF.
How can these findings help improve the design of trials in HFpEF? For trials, the crude, unadjusted, event rates are of most interest. Contrary to what is usually required by trials (ie, a higher entry NT-proBNP for patients with AF), our findings show that it would make more sense to have a minimum NT-proBNP threshold for patients without AF, if the goal is to ensure similarly high rates of relevant events (cardiovascular death and HF hospitalization) in HFpEF patients with and without AF. Our findings clearly show that event rates are low in patients without AF and an NT-proBNP <400 pg/mL (and that few AF patients have NT-proBNP concentrations below that threshold). Patients with low NT-proB-NP were younger, less likely to have a prior HF hospitalization, diabetes mellitus, and myocardial infarction; they also had better kidney function.
But in addition to a minimum threshold for patients without AF, it may also be appropriate to require even higher NT-proBNP thresholds for patients with AF. This is because, in each NT-proBNP band ≥400 pg/mL, mortality rates were lower in AF patients than among patients without AF, but the same was not true for HF hospitalization.
The pathophysiological interpretation of our findings is also of interest. Although the absolute risk of cardiovascular death or death from any cause was lower among patients with AF, compared with those without AF, for a given NT-proBNP level ≥400 pg/mL, the relative increment in risk related to NT-proBNP was similar in patients with and without AF. The opposite was true for HF hospitalization (the main driver also of the composite of cardiovascular death or HF hospitalization) where the absolute risk was relatively high and flat across NT-proBNP bands in patients with AF, compared with those without AF, and the relative risk was, therefore, smaller and also flat. These findings also differ from those reported in patients with HFrEF where the relative increments in risks were similarly steep for death and hospitalization for HF and between patients with and without AF. The reason for these differences between HFpEF and HFrEF are unclear. One possibility is that, in HFrEF, the occurrence of AF may in large part reflect the severity of HF, including greater activation of neurohumoral and other systemic processes, as well as greater cardiac chamber enlargement. In contrast, in patients with HFpEF, the occurrence of AF may not reflect severity of HF-indeed, it often precedes the development of HF. For these reasons, AF may be more closely associated with cardiovascular death in patients with HFrEF than in those with HFpEF. Another possible explanation may relate to differences in history of HF hospitalization observed in patients with HFpEF and HFrEF. In a previous study, we found that a history of prior HF hospitalization was less common in patients with HFrEF and AF compared with those without AF. The opposite was true in the present analysis for HFpEF. This difference may explain why in the adjusted analysis in particular NT-proBNP concentration was less strongly associated with HF hospitalization than with death and less predictive in HFpEF than in HFrEF.
LIMITATIONS
The NT-proBNP bands used were chosen pragmatically, based on the levels used to include patients in ongoing trials, our prior analysis of this question in patients with HFrEF and the need to ensure sufficient numbers of patients and events in each category. Our analyses were not predefined. In TOPCAT, patients enrolled based on NT-proBNP were required to have a level ≥360 pg/ mL which limits the interpretation of the results in the lower bands (although only 9% of patients were from TOPCAT). Finally, patient selection in clinical trials limits the external validity of findings when extrapolating to a typical community-based population.
In summary, few patients with HFpEF and AF have NT-proBNP <400 pg/mL, compared with more than half of those patients who do not have AF. Event rates in patients without AF and with NT-proBNP <400 pg/mL are low. Among patients with NT-proBNP ≥400 pg/mL, the relationship between NT-proBNP and outcomes differs between individuals with and without AF, with lower absolute risk in patients with a high NT-proBNP who have AF compared with those who do not have AF (and a particularly attenuated relative risk of HF hospitalization). Unlike HFrEF, the range of NT-proBNP concentrations and the risk associated with a given concentration differs between HFpEF patients with and without AF.
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